PL439809A1 - Metody wytwarzania przeciwciała anty-alfa4beta7 - Google Patents

Metody wytwarzania przeciwciała anty-alfa4beta7

Info

Publication number
PL439809A1
PL439809A1 PL439809A PL43980920A PL439809A1 PL 439809 A1 PL439809 A1 PL 439809A1 PL 439809 A PL439809 A PL 439809A PL 43980920 A PL43980920 A PL 43980920A PL 439809 A1 PL439809 A1 PL 439809A1
Authority
PL
Poland
Prior art keywords
antibody
methods
vedolizumab
making anti
integrin antibody
Prior art date
Application number
PL439809A
Other languages
English (en)
Inventor
Debra AMELI
Susan R. CARTER
Michael E. DOLAN
Nicole HILO
Amitava Kundu
Amy MILLER
George PARKS
Olga PALEY
Paras BHATIA
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of PL439809A1 publication Critical patent/PL439809A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Przedmiotem zgłoszenia są metody oczyszczania przeciwciała anty-α4β7 przeciwko integrynie, takiego jak wedolizumab, z roztworu płynnego, np. z klarownego zbioru hodowli komórek ssaków. Wynalazek dotyczy m.in. metod oczyszczania w celu kontrolowania ilości substancji związanych z produktem i/lub zanieczyszczeń procesowych obecnych w związanych z oczyszczonych preparatów przeciwciała anty-α4β7 przeciwko integrynie lub jego fragmentu wiążącego antygen, na przykład wedolizumabu. Zgłoszenie obejmuje też kompozycje zawierające przeciwciało anty-α4β7 i ich zastosowania do leczenia zaburzenia.
PL439809A 2019-06-10 2020-06-10 Metody wytwarzania przeciwciała anty-alfa4beta7 PL439809A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962859494P 2019-06-10 2019-06-10
PCT/US2020/037059 WO2020252069A1 (en) 2019-06-10 2020-06-10 METHODS OF PRODUCING AN ANTI-α4β7 ANTIBODY

Publications (1)

Publication Number Publication Date
PL439809A1 true PL439809A1 (pl) 2022-12-05

Family

ID=73781728

Family Applications (1)

Application Number Title Priority Date Filing Date
PL439809A PL439809A1 (pl) 2019-06-10 2020-06-10 Metody wytwarzania przeciwciała anty-alfa4beta7

Country Status (14)

Country Link
US (1) US20220267449A1 (pl)
EP (1) EP3980466A4 (pl)
JP (1) JP2022536486A (pl)
CN (1) CN114375307A (pl)
AR (1) AR119270A1 (pl)
AU (1) AU2020290943A1 (pl)
BR (1) BR112021024897A2 (pl)
CA (1) CA3143167A1 (pl)
IL (1) IL288825A (pl)
MA (1) MA56129A (pl)
MX (1) MX2021015300A (pl)
PL (1) PL439809A1 (pl)
TW (1) TW202112818A (pl)
WO (1) WO2020252069A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019198099A1 (en) * 2018-04-10 2019-10-17 Dr. Reddy's Laboratories Limited Stable antibody formulation
EP4376878A1 (en) * 2021-07-29 2024-06-05 Dr. Reddy's Laboratories Limited Method to control high molecular weight aggregates in an antibody composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2014142882A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive

Also Published As

Publication number Publication date
TW202112818A (zh) 2021-04-01
WO2020252069A1 (en) 2020-12-17
CN114375307A (zh) 2022-04-19
JP2022536486A (ja) 2022-08-17
CA3143167A1 (en) 2020-12-17
MA56129A (fr) 2022-04-13
AR119270A1 (es) 2021-12-09
AU2020290943A1 (en) 2022-02-03
EP3980466A1 (en) 2022-04-13
EP3980466A4 (en) 2023-06-07
MX2021015300A (es) 2022-02-03
US20220267449A1 (en) 2022-08-25
IL288825A (en) 2022-02-01
BR112021024897A2 (pt) 2022-01-18

Similar Documents

Publication Publication Date Title
Levi et al. CD105 protein depletion enhances human adipose-derived stromal cell osteogenesis through reduction of transforming growth factor β1 (TGF-β1) signaling
KR102257356B1 (ko) 치료 단백질의 연속적 정제
PL439809A1 (pl) Metody wytwarzania przeciwciała anty-alfa4beta7
AR122348A2 (es) Métodos y composiciones para tolerancia a herbicidas en plantas
PH12020500549A1 (en) Methods and compositions for ppo herbicide tolerance
PH12020500027A1 (en) Purification of iduronate-2-sulfatase
CN101535469A (zh) 合理设计的细胞培养基
BR112021024848A2 (pt) Métodos de purificação de anticorpos e composições dos mesmos
BR112015009553A2 (pt) Método para separar uma proteína de interesse de uma solução de cultura de células
EA200800565A1 (ru) Взаимодействие moraxella catarrhalis с эпителиальными клетками, внеклеточными матриксными белками и системой комплемента
EA202092088A1 (ru) Антитела анти-phf-тау и их применение
UA115235C2 (uk) Ген токсину axmi335 bacillus thuringiensis та спосіб його застосування
You et al. SOST gene inhibits osteogenesis from adipose-derived mesenchymal stem cells by inducing Th17 cell differentiation
SI2126106T1 (en) A process for the production and purification of factor VIII and its derivatives
HRP20191876T1 (hr) Postupak za povećanje izlučivanja rekombinantnih proteina
MX2015010887A (es) Formulaciones y metodos para aumentar la produccion de proteinas recombinantes.
EA201990789A1 (ru) Новые производные 5-замещенного имидазолилметила
TR2023014436T (tr) Afi̇ni̇te kromatografi̇si̇ i̇le protei̇n saflaştirilmasi
TH143483A (pl)
Poulsen et al. Mammalian perfusion cultivation at high L-Arginine concentration for efficient production of recombinant protein by increasing perfusion filter transmission
Allalasandra et al. Hypoxia Primed Placental Mesenchymal Stem Cells For Wound Healing
LT2014140A (lt) Naujas rekombinantinis antikūnas prieš žmogaus karboanhidrazę xii
BR112023020433A2 (pt) Método para purificar proteínas, intermediário farmacêutico, proteína purificada, proteína cristalizada, preparação farmacêutica, proteína, método de tratamento, proteína para uso e unidade de dosagem
EA202191937A1 (ru) Субстрат для культивирования для способа метанизации
Amid Effects of Extraction, Purification and Freeze Drying Conditions on Enzymatic Properties of Serine Protease from Mango (Mangifera Indica L. Cv. Chokanan) Peel